Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-19
2011-04-19
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S406000, C548S379400, C564S200000, C564S204000, C564S207000
Reexamination Certificate
active
07928134
ABSTRACT:
The invention is directed to 5-(hetero)aryl-4,5-dihydro-(1H)-pyrazole (pyrazoline) derivatives as cannabinoid CB1receptor agonists, to pharmaceutical compositions comprising these compounds, to methods for their syntheses, methods for preparing novel intermediates useful for their syntheses, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, administered to patients to achieve a therapeutic effect in disorders in which CB1receptors are involved, or that can be treated via manipulation of those receptors.Compounds of the present invention include compounds of formula (I):wherein the substituents have the definitions given in the specification.
REFERENCES:
patent: WO 98/05046 (1988-07-01), None
patent: WO 97/21682 (1997-06-01), None
patent: WO 01/29007 (2001-04-01), None
patent: WO 03/020217 (2003-03-01), None
patent: WO 2004/099157 (2004-11-01), None
patent: WO 2005/074920 (2005-08-01), None
patent: WO 2005/077911 (2005-08-01), None
patent: WO 2007/009689 (2007-01-01), None
Kushner et. al., Canadian Journal of Physiology and Pharmacology, 1999, NRC Canada, vol. 77, issue 2, pp. 79-88.
Bach et. al., Tetrahedron, 1994, Pergamon, vol. 50, No. 25, pp. 7543-7556.
Shim, et al., “Molecular Interaction of the Antagonist N-(Piperidin-1-yl)-5-(4-chlorophyenyl)-1-(2,4-dichlorophenyl)-4-mthyl-1H-pyrazole-3-carboxamide with the CB1 Cannabinoid Receptor,”J. Med Chem2002, 45, 1447-1459.
Thomas, et al., “Synthesis of long-chain amide analogs of the cannabinoid CB1receptor antagonistN-(piperidinyl)-5-(4-chlorophyenyl)-1-(2,4-dichlorophyenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities,”Bioorg. Med. Chem13 (2005) 5463-5474.
Li, et al., “Candidate PET radiologands for cannabinoid CB1Receptors: [18f]AM5144 and related pyrazole compounds,”Nuclear Medicine and Biology32 (2005) 361-366.
PCT International Search Report dated Jun. 16, 2009, International Application No. PCT/EP2008/062283.
Written Opinion of the International Searching Authority, dated Jun. 16, 2009, International Application No. PCT/EP2008/062283.
Lange Josephus H. M.
Van Vliet Bernard J.
Zilaout Hicham
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Padmanabhan Sreeni
Pihonak Sarah
Solvay Pharmaceuticals B.V.
LandOfFree
5-aryl-4,5-dihydro-(1H)-pyrazolines as cannabinoid CB1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-aryl-4,5-dihydro-(1H)-pyrazolines as cannabinoid CB1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-aryl-4,5-dihydro-(1H)-pyrazolines as cannabinoid CB1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2667286